Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCG1 | P19174 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 7/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1198655 | 1.00 | PLCG1 (0.42) | PLCG1ELANERAB9ATDP1HTR2A | |
| SCHEMBL14153496 | 1.00 | PLCG1 (0.42) | PLCG1ELANERAB9ATDP1HTR2A | |
| SCHEMBL10013148 | 1.00 | PLCG1 (0.42) | PLCG1ELANERAB9ATDP1HTR2A | |
| SCHEMBL407970 | 1.00 | PLCG1 (0.42) | PLCG1ELANERAB9ATDP1HTR2A | |
| SCHEMBL8695596 | 1.00 | PLCG1 (0.42) | PLCG1ELANERAB9ATDP1HTR2A | |
| SCHEMBL8924773 | 1.00 | PLCG1 (0.42) | PLCG1ELANERAB9ATDP1HTR2A | |
| SCHEMBL13483984 | 1.00 | PLCG1 (0.42) | PLCG1ELANERAB9ATDP1HTR2A | |
| SCHEMBL437737 | 1.00 | PLCG1 (0.42) | PLCG1ELANERAB9ATDP1HTR2A | |
| SCHEMBL18977837 | 0.94 | PLCG1 (0.40) | PLCG1ELANERAB9AHTT | |
| SCHEMBL10013149 | 0.94 | PLCG1 (0.42) | PLCG1ELANERAB9ATDP1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118604173-A | Method for detecting genotoxic impurities in biapenem | 北京悦康科创医药科技股份有限公司 | 2024-09-06 | — | — | CN | claimed |
| EP-4724107-A2 | OPHTHALMIC FILMS | Fount Bio, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12398161-B2 | Continuous preparation method for penem intermediate map | Jilin Asymchem Pharmaceuticals Co., Ltd. (CN) | 2025-08-26 | — | — | US | disclosed |
| EP-3978505-B1 | METHOD FOR CONTINUOUSLY PREPARING MAP PENEM INTERMEDIATE | JILIN ASYMCHEM PHARMACEUTICALS CO LTD (CN) | 2025-07-30 | — | — | EP | disclosed |
| WO-2024254278-A9 | OPHTHALMIC FILMS | FOUNT BIO, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| WO-2024254278-A2 | OPHTHALMIC FILMS | FOUNT BIO, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-12084445-B2 | Broad-spectrum carbapenems | VenatoRx Pharmaceuticals, Inc. (US) | 2024-09-10 | — | — | US | disclosed |
| CN-118604173-A | Method for detecting genotoxic impurities in biapenem | 北京悦康科创医药科技股份有限公司 | 2024-09-06 | — | — | CN | disclosed |
| CN-113710225-B | Delivery and retention of active agents within the skin | 范德生物公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20230127944-A1 | BROAD-SPECTRUM CARBAPENEMS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-04-27 | — | — | US | disclosed |
| US-20090299057-A1 | MEROPENEM INTERMEDIATE IN NOVEL CRYSTALLINE FORM AND A METHOD OF MANUFACTURE OF MEROPENEM | KHEMKA ASHWIN A | 2009-12-03 | — | — | US | disclosed |
| US-20090143574-A1 | Carbapenem Compound | NIPPON SODA CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-7538212-B2 | Intermediate for carbapenem compound for oral administration and process for producing the same | KANEKA CORPORATION (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20090118496-A1 | Crystallization Method for Intermediates of Carbapenem Antibiotics | KANEKA CORPORATION (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20090118496-A1 | Crystallization Method for Intermediates of Carbapenem Antibiotics | KANEKA CORPORATION (JP) | 2009-05-07 | — | — | US | disclosed |
| US-7524952-B2 | Process for producing carbapenem compound for oral administration | KANEKA CORPORATION (JP) | 2009-04-28 | — | — | US | disclosed |
| EP-2006290-A1 | IMPROVED PROCESS FOR PRODUCING CARBAPENEM COMPOUND | Kaneka Corporation (JP) | 2008-12-24 | — | — | EP | disclosed |
| EP-1956027-A1 | CARBAPENEM COMPOUND | NIPPON SODA CO., LTD. (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-20070197781-A1 | PROCESSES FOR THE PREPARATION OF CARBAPENEMS | RANBAXY LABORATORIES LIMITED (IN) | 2007-08-23 | — | — | US | disclosed |
| WO-1996026939-A1 | CARBAPENEM COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12398161-B2 | Continuous preparation method for penem intermediate map | PGM2, POLM, POR | PLCG1 1364/4885ELANE 3800/4885RAB9A 2501/4885 |
| US-20090299057-A1 | MEROPENEM INTERMEDIATE IN NOVEL CRYSTALLINE FORM AND A METHOD OF MANUFACTURE OF MEROPENEM | NT5C3B, CYP4B1, GNE | PLCG1 1999/4885ELANE 3687/4885RAB9A 2703/4885 |
| US-20090118496-A1 | Crystallization Method for Intermediates of Carbapenem Antibiotics | OTUB1, PYCARD, OTUD7B | PLCG1 3317/4885ELANE 3442/4885RAB9A 3963/4885 |
| US-20090143574-A1 | Carbapenem Compound | MGAM, SI, PDS5A | PLCG1 3321/4885ELANE 2247/4885RAB9A 2019/4885 |
| US-20230127944-A1 | BROAD-SPECTRUM CARBAPENEMS | MGAM, ALPI, SI | PLCG1 1243/4885ELANE 690/4885RAB9A 1009/4885 |
| US-20070197781-A1 | PROCESSES FOR THE PREPARATION OF CARBAPENEMS | MGAM, SI, TREH | PLCG1 1770/4885ELANE 2492/4885RAB9A 2331/4885 |
| US-12084445-B2 | Broad-spectrum carbapenems | MGAM, ALPI, SI | PLCG1 1243/4885ELANE 690/4885RAB9A 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.